Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) - April 7, 2025 Deadline to Join - Contact Levi & Korsinsky
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action lawsuit against Neumora Therapeutics (NMRA) alleging the company made false statements and concealed critical information about its Phase Two clinical trials for Navacaprant, a therapeutic candidate for Major Depressive Disorder (MDD). The lawsuit claims Neumora manipulated trial inclusion criteria and statistical analysis to show potential efficacy, with potential securities law violations.
March 23, 2025 | 3:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The class action lawsuit alleges manipulation of clinical trial data for Navacaprant, which could negatively impact investor confidence and the company's stock price.
The lawsuit directly targets Neumora Therapeutics, alleging securities law violations related to clinical trial data presentation. Such legal actions typically create investor uncertainty and can lead to stock price decline.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100